2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Inhaler device feature preferences among patients with obstructive lung diseases : A systematic review and meta-analysis

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background:

          Bronchodilators administered through inhalation devices are the mainstay treatment for patients with obstructive lung diseases. Patients do not view devices as interchangeable. This systematic review and meta-analysis examined device feature preferences among patients with obstructive lung diseases treated with handheld inhalers.

          Study Appraisal and Synthesis Methods:

          PubMed, EMBASE, PsycINFO, Cochrane, and Google Scholar were searched to identify publications between 2010 and 2019 that met the following criteria:

          • (1)

            English language;

          • (2)

            studied adults with chronic obstructive pulmonary disease, bronchitis, or emphysema; and

          • (3)

            reported patients’ device feature preferences specific to metered-dose inhalers, dry powder inhalers, and soft mist inhalers.

          A manual search extended the study period from 2001 to 2019. Random-effects models were used to generate pooled mean effect sizes and 95% confidence intervals (CIs) for preferred device features. Heterogeneity was measured by the I 2 statistic.

          Results:

          Nineteen studies (n = 11,256) were included in this meta-analysis. Average age ranged from 50.4 to 74.3 years. The majority of patients were male (57%) and had chronic obstructive pulmonary disease (92%).

          Patients preferred the following device features:

          • (1)

            small size (71.7%, 95% CI: 46.3, 97.1; n = 604, 3 studies);

          • (2)

            rapid medication administration (64.9%, 95% CI: 36.5, 93.4; n = 745, 3 studies);

          • (3)

            durability (62.1%, 95% CI: 39.7, 84.4; n = 4,500, 4 studies);

          • (4)

            a dose counter (52.3%, 95% CI: 20.7, 83.9; n = 4,536, 4 studies);

          • (5)

            portability (51.8%, 95% CI: 29.1, 74.5; n = 4,975, 7 studies);

          • (6)

            perceived ease of use (51.2%, 95% CI: 35.6, 66.7; n = 5,878, 10 studies); and

          • (7)

            perceived ease of dose preparation (50.1%, 95% CI: 26.2, 73.9; n = 4,003, 4 studies).

          Conclusions and Implications of Key Findings:

          Adults with obstructive lung diseases preferred small inhaler devices that were portable, durable, perceived as easy to use, and fast in medication administration. Healthcare providers should give due consideration to the patient's device feature preferences when developing a treatment plan that prescribes an inhalation device.

          Related collections

          Most cited references37

          • Record: found
          • Abstract: not found
          • Article: not found

          Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found
            Is Open Access

            Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD.

            Suboptimal adherence to pharmacological treatment of asthma and chronic obstructive pulmonary disease (COPD) has adverse effects on disease control and treatment costs. The reasons behind non-adherence revolve around patient knowledge/education, inhaler device convenience and satisfaction, age, adverse effects and medication costs. Age is of particular concern given the increasing prevalence of asthma in the young and increased rates of non-adherence in adolescents compared with children and adults. The correlation between adherence to inhaled pharmacological therapies for asthma and COPD and clinical efficacy is positive, with improved symptom control and lung function shown in most studies of adults, adolescents and children. Satisfaction with inhaler devices is also positively correlated with improved adherence and clinical outcomes, and reduced costs. Reductions in healthcare utilisation are consistently observed with good adherence; however, costs associated with general healthcare and lost productivity tend to be offset only in more adherent patients with severe disease, versus those with milder forms of asthma or COPD. Non-adherence is associated with higher healthcare utilisation and costs, and reductions in health-related quality of life, and remains problematic on an individual, societal and economic level. Further development of measures to improve adherence is needed to fully address these issues. Copyright © 2013. Published by Elsevier Ltd.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Chronic obstructive pulmonary disease exacerbation and inhaler device handling: real-life assessment of 2935 patients.

              Acute exacerbations of chronic obstructive pulmonary disease (COPD) can be prevented by inhaled treatment. Errors in inhaler handling, not taken into account in clinical trials, could impact drug delivery and minimise treatment benefit. We aimed to assess real-life inhaler device handling in COPD patients and its association with COPD exacerbations.To this end, 212 general practitioners and 50 pulmonologists assessed the handling of 3393 devices used for continuous treatment of COPD in 2935 patients. Handling errors were observed in over 50% of handlings, regardless of the device used. Critical errors compromising drug delivery were respectively made in 15.4%, 21.2%, 29.3%, 43.8%, 46.9% and 32.1% of inhalation assessment tests with Breezhaler® (n=876), Diskus® (n=452), Handihaler® (n=598), pressurised metered-dose inhaler (pMDI) (n=422), Respimat® (n=625) and Turbuhaler® (n=420).The proportion of patients requiring hospitalisation or emergency room visits in the past 3 months for severe COPD exacerbation was 3.3% (95% CI 2.0-4.5) in the absence of error and 6.9% (95% CI 5.3-8.5) in the presence of critical error (OR 1.86, 95% CI 1.14-3.04, p<0.05).Handling errors of inhaler devices are underestimated in real life and are associated with an increased rate of severe COPD exacerbation. Training in inhaler use is an integral part of COPD management.
                Bookmark

                Author and article information

                Journal
                Medicine (Baltimore)
                Medicine (Baltimore)
                MEDI
                Medicine
                Wolters Kluwer Health
                0025-7974
                1536-5964
                19 June 2020
                19 June 2020
                : 99
                : 25
                : e20718
                Affiliations
                [a ]Consulting at McCann Health, New York, NY
                [b ]Columbia University, School of Professional Studies, Applied Analytics Program, New York, NY
                [c ]Global Health Economics and Outcomes Research, Sunovion Pharmaceuticals Inc., Marlborough, MA
                [d ]Advance Health Solutions, LLC, New York, NY
                [e ]Chronic Obstructive Pulmonary Disease Center, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
                Author notes
                []Correspondence: Maryam Navaie, Columbia University, School of Professional Studies, Applied Analytics Program, 2970 Broadway, Lewisohn Hall #203, New York, NY 10027, (e-mail: mn2918@ 123456columbia.edu ).
                Author information
                http://orcid.org/0000-0001-9773-3267
                Article
                MD-D-19-09234 20718
                10.1097/MD.0000000000020718
                7310962
                32569208
                1a2d5cb5-1fd1-4047-bb55-c30235a4bdd7
                Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc.

                This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0

                History
                : 3 December 2019
                : 22 March 2020
                : 9 May 2020
                Funding
                Funded by: Sunovion Pharmaceuticals, Inc.
                Award ID: N/A
                Award Recipient : Maryam Navaie
                Categories
                6700
                Research Article
                Meta-Analysis of Observational Studies in Epidemiology
                Custom metadata
                TRUE

                chronic obstructive pulmonary disease,device feature preferences,handheld inhaler,meta-analysis,obstructive lung disease,systematic review

                Comments

                Comment on this article